The role of microglia in the pathogenesis of multiple sclerosis
https://doi.org/10.14412/2074-2711-2026-1-4-13
Abstract
Microglia are currently considered to be the main representatives of myeloid cells in the central nervous system (CNS) and perform a number of homeostatic functions. In response to damaging effects and changes in the CNS, microglia are activated and can perform both neuroinflammatory and neuroprotective roles. A number of studies indicate that chronic activation of microglia contributes to the development of demyelinating diseases. This review examines the contribution of microglia to the development and progression of multiple sclerosis, analyses its involvement in the demyelination process, and discusses potential therapeutic approaches aimed at modulating its activity.
Keywords
Supporting agencies: The investigation has not been sponsored
About the Authors
A. E. Karchevskaya
Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Anna Yevgenyevna Karchevskaya
117485; 5A, Butlerova St.; 119991; 8, Trubetskaya St., Build. 2; Moscow
Competing Interests:
There are no conflicts of interest
Sh. R. Nabiev
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
119991; 8, Trubetskaya St., Build. 2; Moscow
Competing Interests:
There are no conflicts of interest
I. Yu. Oganesyan
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
119991; 8, Trubetskaya St., Build. 2; Moscow
Competing Interests:
There are no conflicts of interest
O. N. Voskresenskaya
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
119991; 8, Trubetskaya St., Build. 2; Moscow
Competing Interests:
There are no conflicts of interest
References
1. Jia Y, Zhang D, Li H, et al. Activation of FXR by ganoderic acid A promotes remyelination in multiple sclerosis via anti-inflammation and regeneration mechanism. Biochem Pharmacol. 2021;185:114422. doi: 10.1016/j.bcp.2021.114422
2. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002
3. Melnikov MV, Sviridova AA, Rogovskii VS, Boyko AN, Pashenkov MV. The role of macrophages in the development of neuroinflammation in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(5):51-6 (In Russ.). doi: 10.17116/jnevro202212205151
4. Prineas JW, Lee S. Microglia subtypes in acute, subacute, and chronic multiple sclerosis. J Neuropathol Exp Neurol. 2023;82(8):674-94. doi: 10.1093/jnen/nlad046
5. Prineas JW, Parratt JD. Multiple sclerosis: microglia, monocytes, and macrophage-mediated demyelination. J Neuropathol Exp Neurol. 2021;80(10):975-96. doi: 10.1093/jnen/nlab083
6. Kuhlmann T, Moccia M, Coetzee T, et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023;22(1):78-88. doi: 10.1016/S1474-4422(22)00289-7
7. Dobson R, Giovannoni G. Multiple sclerosis – a review. Eur J Neurol. 2019;26(1):27-40. doi: 10.1111/ene.13819
8. Voet S, Prinz M, van Loo G. Microglia in central nervous system inflammation and multiple sclerosis pathology. Trends Mol Med. 2019;25(2):112-23. doi: 10.1016/j.molmed.2018.11.005
9. El Mahdaoui S, Husted SR, Hansen MB, et al. Cerebrospinal fluid soluble CD27 is associated with CD8+ T cells, B cells and biomarkers of B cell activity in relapsing-remitting multiple sclerosis. J Neuroimmunol. 2023;381:578128. doi: 10.1016/j.jneuroim.2023.578128
10. Sloane E, Ledeboer A, Seibert W, et al. Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental Multiple Sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy. Brain Behav Immun. 2009;23(1):92-100. doi: 10.1016/j.bbi.2008.09.004
11. Maroto-Garcia J, Martinez-Escribano A, Delgado-Gil V, et al. Biochemical biomarkers for multiple sclerosis. Clin Chim Acta. 2023;117471. doi: 10.1016/j.cca.2023.1174711
12. Guerrero BL, Sicotte NL. Microglia in Multiple Sclerosis: Friend or Foe? Front Immunol. 2020;11:374. doi: 10.3389/fimmu.2020.00374
13. Walsh AD, Nguyen LT, Binder MD. miRNAs in microglia: important players in multiple sclerosis pathology. ASN Neuro. 2021;13:1759091420981182. doi: 10.1177/1759091420981182
14. Yong VW. Microglia in multiple sclerosis: Protectors turn destroyers. Neuron. 2022;110(21):3534-48. doi: 10.1016/j.neuron.2022.06.023
15. Sen MK, Mahns DA, Coorssen JR, Shortland PJ. The roles of microglia and astrocytes in phagocytosis and myelination: Insights from the cuprizone model of multiple sclerosis. Glia. 2022;70(7):1215-50. doi: 10.1002/glia.24148
16. Talebi F, Ghorbani S, Chan WF, et al. MicroRNA-142 regulates inflammation and T cell differentiation in an animal model of multiple sclerosis. J Neuroinflammation. 2017;14:1-14. doi: 10.1186/s12974-017-0832-7
17. Chaudhuri AD, Yelamanchili SV, Marcondes MCG, Fox HS. Up-regulation of microRNA-142 in simian immunodeficiency virus encephalitis leads to repression of sirtuin1. FASEB J. 2013;27(9):3720. doi: 10.1096/fj.13-232678
18. Kessler W, Thomas C, Kuhlmann T. Microglia activation in periplaque white matter in multiple sclerosis depends on age and lesion type, but does not correlate with oligoden-droglial loss. Acta Neuropathologica. 2023;146(6):817-28. doi: 10.1007/s00401-023-02645-2
19. Michailidou I, Willems JG, Kooi E, et al. Complement C 1q-C 3-associated synaptic changes in multiple sclerosis hippocampus. Ann Neurol. 2015;77(6): 1007-26. doi: 10.1002/ana.24398
20. Sherafat A, Pfeiffer F, Reiss AM, et al. Microglial neuropilin-1 promotes oligodendrocyte expansion during development and remyelination by trans-activating platelet-derived growth factor receptor. Nature Communicat. 2021;12(1):2265. doi: 10.1038/s41467-021-22532-2
21. Van Wageningen TA, Vlaar E, Kooij G, et al. Regulation of microglial TMEM119 and P2RY12 immunoreactivity in multiple sclerosis white and grey matter lesions is dependent on their inflammatory environment. Acta Neuropathol Commun. 2019;7:1-16. doi: 10.1186/s40478-019-0850-z
22. Nuesslein-Hildesheim B, Ferrero E, Schmid C, et al. Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis. J Neuroinflammation. 2023;20(1):194. doi: 10.1186/s12974-023-02877-9
23. Cignarella F, Filipello F, Bollman B, et al. TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis. Acta Neuropathologica. 2020;140:513-34. doi: 10.1007/s00401-020-02193-z
24. Masuda T, Sankowski R, Staszewski O, et al. Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature. 2019;566(7744):388-92. doi: 10.1038/s41586-019-0924-x
25. Fiedler T, Fairless R, Pichi K, et al. Co-modulation of TNFR1 and TNFR2 in an animal model of multiple sclerosis. J Neuroinflammation. 2023;20(1):100. doi: 10.1186/s12974-023-02784-z
26. Pegoretti V, Bauer J, Fischer R, et al. Sequential treatment with a TNFR2 agonist and a TNFR1 antagonist improves outcomes in a humanized mouse model for MS. J Neuroinflammation. 2023;20(1):106. doi: 10.1186/s12974-023-02785-y
27. Tsouki F, Williams A. Multifaceted involvement of microglia in gray matter pathology in multiple sclerosis. Stem Cells. 2021;39(8):993-1007. doi: 10.1002/stem.3374
28. Zrzavy T, Hametner S, Wimmer I, et al. Loss of “homeostatic” microglia and patterns of their activation in active multiple sclerosis. Brain. 2017;140(7):1900-13. doi: 10.1093/brain/awx113
29. Gomez Morillas A, Besson VC, Lerouet D. Microglia and neuroinflammation: what place for P2RY12? Int J Mol Sci. 2021;22(4):1636. doi: 10.3390/ijms22041636
30. Mercurio D, Fumagalli S, Schafer MK, et al. Protein expression of the microglial marker Tmem119 decreases in association with morphological changes and location in a mouse model of traumatic brain injury. Front Cell Neurosci. 2022;16:820127. doi: 10.3389/fncel.2022.820127
31. Gruchot J, Weyers V, Göttle P, et al. The molecular basis for remyelination failure in multiple sclerosis. Cells. 2019;8(8):825. doi: 10.3390/cells8080825
32. Ton AMM, Vasconcelos CCF, Alvarenga RMP. Benign multiple sclerosis: aspects of cognition and neuroimaging. Arquivos de Neuro-Psiquiatria. 2017;75(6):394-401. doi: 10.1590/0004-282x20170043
33. Kapkanets DV, Belov SE, Dolgushin MB, Boyko AN. Paramagnetic rim sign in multiple sclerosis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(4):94-9 (In Russ.). doi: 10.14412/2074-2711-2023-4-94-99
34. Garcia-Hernandez R, Cerdan Cerda A, Trouve Carpena A, et al. Mapping microglia and astrocyte activation in vivo using diffusion MRI. Sci Adv. 2022;8(21):eabq2923. doi: 10.1126/sciadv.abq2923
35. Chataway J, Williams T, Li V, et al. Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges. Lancet Neurol. 2024;23(3):277-301. doi: 10.1016/S1474-4422(24)00027-9
36. Abourbeh G, Theze B, Maroy R, et al. Imaging microglial/macrophage activation in spinal cords of experimental autoimmune encephalomyelitis rats by positron emission tomography using the mitochondrial 18 kDa translocator protein radioligand [18F]DPA-714. J Neurosci. 2012;32(17):5728-36. doi: 10.1523/JNEUROSCI.2900-11.2012
37. Hamzaoui M, Garcia J, Boffa G, et al. Positron Emission Tomography with [(18) F]-DPA-714 Unveils a Smoldering Component in Most Multiple Sclerosis Lesions which Drives Disease Progression. Ann Neurol. 2023;94(2):366-83. doi: 10.1002/ana.26657
38. Van der Weijden CWJ, Meilof JF, van der Hoorn A, et al. The Future of PET Imaging in Multiple Sclerosis: Characterisation of Individual White Matter Lesions. J Clin Med. 2025;14(13). doi: 10.3390/jcm14134439
39. Cantoni C, Bollman B, Licastro D, et al. TREM2 regulates microglial cell activation in response to demyelination in vivo. Acta Neuropathologica. 2015;129:429-47. doi: 10.1007/s00401-015-1388-1
40. Zetterberg H. Fluid biomarkers for microglial activation and axonal injury in multiple sclerosis. Acta Neurol Scand. 2017;136:15-7. doi: 10.1111/ane.12845
41. Öhrfelt A, Axelsson M, Malmeström C, et al. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. Mult Scler. 2016 Oct;22(12):1587-95. doi: 10.1177/1352458515624558
42. Ioannides ZA, Csurhes PA, Swayne A, et al. Correlations between macrophage/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis. Mult Scler J Exp Transl Clin. 2021 Jun 3;7(2):20552173211019772. doi: 10.1177/20552173211019772
43. Rival M, Galoppin M, Thouvenot E. Biological markers in early multiple sclerosis: the paved way for radiologically isolated syndrome. Front Immunol. 2022;13:866092. doi: 10.3389/fimmu.2022.866092
44. Beliёn J, Swinnen S, D’hondt R, et al. CHIT1 at diagnosis predicts faster disability progression and reflects early microglial activation in multiple sclerosis. Nat Commun. 2024;15(1):5013. doi: 10.1038/s41467-024-49312-y
45. Vankriekelsvenne E, Chrzanowski U, Manzhula K, et al. Transmembrane protein 119 is neither a specific nor a reliable marker for microglia. Glia. 2022;70(6):1170-90. doi: 10.1002/glia.24164
46. Reich DS, Arnold DL, Vermersch P, et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021;20(9):729-38. doi: 10.1016/s1474-4422(21)00237-4
47. Martin E, Aigrot MS, Grenningloh R, et al. Brutonуs tyrosine kinase inhibition promotes myelin repair. Brain Plasticity. 2019;5(2):123-33. doi: 10.3233/bpl-200100
48. Gruber R, Blazier A, Lee L, et al. Evaluating the effect of btk inhibitor tolebrutinib in human tri-culture (P1-1. Virtual). Neurology. 2022;98(18_supplement):2594. doi: 10.1212/WNL.98.18_supplement.2594
49. Krämer J, Bar-Or A, Turner TJ, Wiendl H. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat Rev Neurol. 2023;19(5):289-304. doi: 10.1038/s41582-023-00800-7
50. Langlois J, Lange S, Ebeling M, et al. Fenebrutinib, a Brutonуs tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways. J Neuroinflammation. 2024;21(1):276. doi: 10.1186/s12974-024-03267-5
51. Bar-Or A, Dufek M, Budincevic H, et al. Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study. Lancet Neurol. 2025;24(8):656-66. doi: 10.1016/s1474-4422(25)00174-7
52. Fox RJ, Bar-Or A, Traboulsee A, et al; HERCULES Trial Group. Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis. N Engl J Med. 2025 May 15;392(19):1883-92. doi: 10.1056/NEJMoa2415988
53. Montalban X, Vermersch P, Arnold DL, et al. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol. 2024;23(11):1119-32. doi: 10.1016/s1474-4422(24)00328-4
54. Gruchot J, Lein F, Lewen I, et al. Siponimod modulates the reaction of microglial cells to pro-inflammatory stimulation. Int J Mol Sci. 2022;23(21):13278. doi: 10.3390/ijms232113278
55. O’Sullivan C, Schubart A, Mir AK, Dev KK. The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures. J Neuroinflammation. 2016;13:1-14. doi: 10.1186/s12974-016-0494-x
56. Noda H, Takeuchi H, Mizuno T, Suzumura A. Fingolimod phosphate promotes the neuroprotective effects of microglia. J Neuroimmunol. 2013;256(1-2):13-8. doi: 10.1016/j.jneuroim.2012.12.005
57. Dietrich M, Hecker C, Martin E, et al. Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models. Neurol Neuroimmunol Neuroinflammat. 2022;9(3):e1161. doi: 10.1212/NXI.0000000000001161
58. Jorgensen LO, Hyrlov K, Elkjaer M, et al. Cladribine modifies functional properties of microglia. Clin Exp Immunol. 2020;201(3):328-40. doi: 10.1111/cei.13473
59. Aybar F, Perez MJ, Marcora MS, et al. 2-Chlorodeoxyadenosine (Cladribine) preferentially inhibits the biological activity of microglial cells. Int Immunopharmacol. 2022;105: 108571. doi: 10.1016/j.intimp.2022.108571
60. Singh V, Voss EV, Benardais K, Stangel M. Effects of 2-chlorodeoxyadenosine (Cladribine) on primary rat microglia. J Neuroimmun Pharmacol. 2012;7:939-50. doi: 10.1007/s11481-012-9387-7
61. Bakhtiyarova KZ, Boyko AN, Vlasov YaV, et al. Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(3):93-9 (In Russ.). doi: 10.14412/2074-2711-2020-3-93-99
62. Boyko AN, Boyko OV. Cladribine tabletsу potential role as a key example of selective immune reconstitution therapy in multiple sclerosis. Degener Neurol Neuromuscul Dis. 2018 May 3;8:35-44. doi: 10.2147/DNND.S161450
63. Giovannoni G, Boyko A, Correale J, et al. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. Neurodegener Dis Manag. 2023;13(5):261-8. doi: 10.2217/nmt-2023-0018
64. Giovannoni G, Boyko A, Correale J, et al. Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort. Mult Scler. 2025;31(1):44-58. doi: 10.1177/13524585241302170
65. Tastan B, Arioz BI, Tufekci KU, et al. Dimethyl fumarate alleviates NLRP3 inflammasome activation in microglia and sickness behavior in LPS-challenged mice. Front Immunol. 2021;12:737065. doi: 10.3389/fimmu.2021.737065
66. Rosito M, Testi C, Parisi G, et al. Exploring the use of dimethyl fumarate as microglia modulator for neurodegenerative diseases treatment. Antioxidants. 2020;9(8):700. doi: 10.3390/antiox9080700
67. Melnikov MV, Sharanova SN, Konovalova OE, et al. The effect of glatiramer acetate on the functioning of Th1 and Th17 cells in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;8(2):151-8 (In Russ.). doi: 10.17116/jnevro2018118082121
68. Sellebjerg F, Cadavid D, Steiner D, et al. Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. Ther Adv Neurol Disord. 2016;9(1):31-43. doi: 10.1177/1756285615615257
69. Mindur JE, Ito N, Dhib-Jalbut S, Ito K. Early treatment with anti-VLA-4 mAb can prevent the infiltration and/or development of pathogenic CD11b<sup>+</sup> CD4<sup>+</sup> T cells in the CNS during progressive EAE. PloS One. 2014;9(6):e99068. doi: 10.1371/journal.pone.0099068
70. De Kleijn KMA, Martens GJM. Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System. Int J Mol Sci. 2020;21(12):4229. doi: 10.3390/ijms21124229
71. Pul R, Moharregh-Khiabani D, Skuljec J, et al. Glatiramer acetate modulates TNF-α and IL-10 secretion in microglia and promotes their phagocytic activity. J Neuroimmun Pharmacol. 2011;6:381-8. doi: 10.1007/s11481-010-9248-1
72. Ten Bosch GJ, Bolk J, Фt Hart BA, Laman JD. Multiple sclerosis is linked to MAPKERK overactivity in microglia. J Mol Med. 2021;99(8):1033-42. doi: 10.1007/s00109-021-02080-4
73. Konen FF, Möhn N, Witte T, et al. Treatment of autoimmunity: the impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. Autoimmun Rev. 2023;22(5):103312. doi: 10.1016/j.autrev.2023.103312
Review
For citations:
Karchevskaya AE, Nabiev SR, Oganesyan IY, Voskresenskaya ON. The role of microglia in the pathogenesis of multiple sclerosis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2026;18(1):4-13. (In Russ.) https://doi.org/10.14412/2074-2711-2026-1-4-13
Views:
492
JATS XML
Email this article 